Jiangsu Hengrui Medicine Co Ltd Net Assets
Jiangsu Hengrui Medicine Co Ltd net assets. Based on the latest financial reports, Jiangsu Hengrui Medicine Co Ltd (600276) has net assets worth CN¥60.03 Billion CNY (≈ $8.78 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥68.33 Billion ≈ $10.00 Billion USD) and total liabilities (CN¥8.30 Billion ≈ $1.21 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 600276 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥60.03 Billion |
| % of Total Assets | 87.86% |
| Annual Growth Rate | 25.71% |
| 5-Year Change | 49.71% |
| 10-Year Change | 344.98% |
| Growth Volatility | 56.16 |
Net Assets of Jiangsu Hengrui Medicine Co Ltd (1997–2024)
Net assets of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024. This chart illustrates how Jiangsu Hengrui Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. See Jiangsu Hengrui Medicine Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Jiangsu Hengrui Medicine Co Ltd (1997–2024)
The table below shows the annual net assets of Jiangsu Hengrui Medicine Co Ltd from 1997 to 2024. For live market cap and overall valuation, see 600276 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥46.09 Billion ≈ $6.74 Billion |
+12.32% |
| 2023-12-31 | CN¥41.03 Billion ≈ $6.00 Billion |
+6.82% |
| 2022-12-31 | CN¥38.41 Billion ≈ $5.62 Billion |
+7.99% |
| 2021-12-31 | CN¥35.57 Billion ≈ $5.21 Billion |
+15.54% |
| 2020-12-31 | CN¥30.79 Billion ≈ $4.51 Billion |
+23.46% |
| 2019-12-31 | CN¥24.94 Billion ≈ $3.65 Billion |
+25.96% |
| 2018-12-31 | CN¥19.80 Billion ≈ $2.90 Billion |
+24.18% |
| 2017-12-31 | CN¥15.94 Billion ≈ $2.33 Billion |
+23.84% |
| 2016-12-31 | CN¥12.87 Billion ≈ $1.88 Billion |
+24.30% |
| 2015-12-31 | CN¥10.36 Billion ≈ $1.52 Billion |
+24.94% |
| 2014-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
+24.55% |
| 2013-12-31 | CN¥6.66 Billion ≈ $973.96 Million |
+22.29% |
| 2012-12-31 | CN¥5.44 Billion ≈ $796.41 Million |
+24.30% |
| 2011-12-31 | CN¥4.38 Billion ≈ $640.72 Million |
+26.01% |
| 2010-12-31 | CN¥3.47 Billion ≈ $508.48 Million |
+30.39% |
| 2009-12-31 | CN¥2.67 Billion ≈ $389.98 Million |
+31.64% |
| 2008-12-31 | CN¥2.02 Billion ≈ $296.24 Million |
+23.96% |
| 2007-12-31 | CN¥1.63 Billion ≈ $238.99 Million |
+29.94% |
| 2006-12-31 | CN¥1.26 Billion ≈ $183.92 Million |
+13.43% |
| 2005-12-31 | CN¥1.11 Billion ≈ $162.15 Million |
+11.03% |
| 2004-12-31 | CN¥998.05 Million ≈ $146.05 Million |
+10.48% |
| 2003-12-31 | CN¥903.35 Million ≈ $132.19 Million |
+11.53% |
| 2002-12-31 | CN¥809.97 Million ≈ $118.52 Million |
+6.86% |
| 2001-12-31 | CN¥757.99 Million ≈ $110.92 Million |
+12.70% |
| 2000-12-31 | CN¥672.57 Million ≈ $98.42 Million |
+313.79% |
| 1999-12-31 | CN¥162.54 Million ≈ $23.78 Million |
+14.84% |
| 1998-12-31 | CN¥141.53 Million ≈ $20.71 Million |
+48.13% |
| 1997-12-31 | CN¥95.54 Million ≈ $13.98 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Hengrui Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 138979.2% over the analyzed period, indicating profitable operations and earnings retention.
Jiangsu Hengrui Medicine Co Ltd Net Assets Breakdown (December 2024)
Jiangsu Hengrui Medicine Co Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥33.87 Billion | 74.40% |
| Common Stock | CN¥6.38 Billion | 14.01% |
| Other Comprehensive Income | CN¥16.97 Million | 0.04% |
| Other Components | CN¥5.26 Billion | 11.55% |
| Total Equity | CN¥45.52 Billion | 100.00% |
Jiangsu Hengrui Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Jiangsu Hengrui Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ArcelorMittal SA ADR
NYSE:MT
|
$45.32 Billion |
|
Sun Life Financial Inc.
TO:SLF
|
$45.35 Billion |
|
Ciena Corp
NYSE:CIEN
|
$45.40 Billion |
|
eBay Inc
NASDAQ:EBAY
|
$45.53 Billion |
|
Westinghouse Air Brake Technologies Corp
NYSE:WAB
|
$45.10 Billion |
|
Commerzbank AG
F:ZZMS
|
$44.96 Billion |
|
Cheniere Energy Inc
NYSE MKT:LNG
|
$44.96 Billion |
|
Ambev S.A
MX:ABEVN
|
$44.94 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Hengrui Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,465,795,358 to 45,519,861,860, a change of 5,054,066,502 (12.5%).
- Net income of 6,336,527,014 contributed positively to equity growth.
- Dividend payments of 1,274,788,274 reduced retained earnings.
- Share repurchases of 228,426,456 reduced equity.
- Other comprehensive income decreased equity by 2,352,162.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥6.34 Billion | +13.92% |
| Dividends Paid | CN¥1.27 Billion | -2.8% |
| Share Repurchases | CN¥228.43 Million | -0.5% |
| Other Comprehensive Income | CN¥-2.35 Million | -0.01% |
| Other Changes | CN¥223.11 Million | +0.49% |
| Total Change | CN¥- | 12.49% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Hengrui Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1717.56x to 6.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1997-12-31 | CN¥0.03 | CN¥48.46 | x |
| 1998-12-31 | CN¥0.04 | CN¥48.46 | x |
| 1999-12-31 | CN¥0.05 | CN¥48.46 | x |
| 2000-12-31 | CN¥0.20 | CN¥48.46 | x |
| 2001-12-31 | CN¥0.22 | CN¥48.46 | x |
| 2002-12-31 | CN¥0.24 | CN¥48.46 | x |
| 2003-12-31 | CN¥0.27 | CN¥48.46 | x |
| 2004-12-31 | CN¥0.29 | CN¥48.46 | x |
| 2005-12-31 | CN¥0.33 | CN¥48.46 | x |
| 2006-12-31 | CN¥0.20 | CN¥48.46 | x |
| 2007-12-31 | CN¥0.26 | CN¥48.46 | x |
| 2008-12-31 | CN¥0.32 | CN¥48.46 | x |
| 2009-12-31 | CN¥0.42 | CN¥48.46 | x |
| 2010-12-31 | CN¥0.54 | CN¥48.46 | x |
| 2011-12-31 | CN¥0.67 | CN¥48.46 | x |
| 2012-12-31 | CN¥0.83 | CN¥48.46 | x |
| 2013-12-31 | CN¥1.01 | CN¥48.46 | x |
| 2014-12-31 | CN¥1.26 | CN¥48.46 | x |
| 2015-12-31 | CN¥1.57 | CN¥48.46 | x |
| 2016-12-31 | CN¥1.96 | CN¥48.46 | x |
| 2017-12-31 | CN¥2.41 | CN¥48.46 | x |
| 2018-12-31 | CN¥3.07 | CN¥48.46 | x |
| 2019-12-31 | CN¥3.91 | CN¥48.46 | x |
| 2020-12-31 | CN¥4.80 | CN¥48.46 | x |
| 2021-12-31 | CN¥5.49 | CN¥48.46 | x |
| 2022-12-31 | CN¥5.94 | CN¥48.46 | x |
| 2023-12-31 | CN¥6.40 | CN¥48.46 | x |
| 2024-12-31 | CN¥7.18 | CN¥48.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Hengrui Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.92%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.64%
- • Asset Turnover: 0.56x
- • Equity Multiplier: 1.10x
- Recent ROE (13.92%) is below the historical average (19.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1997 | 43.58% | 13.53% | 1.05x | 3.07x | CN¥31.65 Million |
| 1998 | 30.94% | 11.88% | 1.00x | 2.62x | CN¥29.26 Million |
| 1999 | 32.00% | 12.40% | 0.89x | 2.89x | CN¥35.29 Million |
| 2000 | 9.74% | 13.47% | 0.49x | 1.47x | CN¥-1.77 Million |
| 2001 | 10.92% | 12.80% | 0.57x | 1.51x | CN¥6.85 Million |
| 2002 | 9.97% | 10.44% | 0.63x | 1.52x | CN¥-256.01K |
| 2003 | 10.66% | 9.00% | 0.72x | 1.64x | CN¥5.85 Million |
| 2004 | 12.46% | 10.71% | 0.91x | 1.28x | CN¥24.24 Million |
| 2005 | 14.82% | 13.76% | 0.92x | 1.17x | CN¥52.72 Million |
| 2006 | 16.59% | 14.53% | 0.98x | 1.17x | CN¥82.10 Million |
| 2007 | 25.56% | 21.07% | 0.97x | 1.25x | CN¥251.35 Million |
| 2008 | 21.21% | 17.68% | 1.06x | 1.13x | CN¥223.51 Million |
| 2009 | 25.53% | 21.98% | 1.01x | 1.15x | CN¥404.96 Million |
| 2010 | 21.38% | 19.34% | 0.96x | 1.15x | CN¥385.44 Million |
| 2011 | 20.75% | 19.26% | 0.94x | 1.14x | CN¥454.19 Million |
| 2012 | 20.66% | 19.82% | 0.92x | 1.13x | CN¥555.97 Million |
| 2013 | 19.48% | 19.96% | 0.86x | 1.14x | CN¥602.39 Million |
| 2014 | 19.10% | 20.34% | 0.82x | 1.15x | CN¥722.13 Million |
| 2015 | 21.87% | 23.31% | 0.81x | 1.16x | CN¥1.18 Billion |
| 2016 | 20.90% | 23.34% | 0.77x | 1.16x | CN¥1.35 Billion |
| 2017 | 20.93% | 23.25% | 0.77x | 1.17x | CN¥1.68 Billion |
| 2018 | 20.61% | 23.34% | 0.78x | 1.13x | CN¥2.09 Billion |
| 2019 | 21.51% | 22.88% | 0.85x | 1.11x | CN¥2.85 Billion |
| 2020 | 20.75% | 22.82% | 0.80x | 1.14x | CN¥3.28 Billion |
| 2021 | 12.94% | 17.49% | 0.66x | 1.12x | CN¥1.03 Billion |
| 2022 | 10.33% | 18.36% | 0.50x | 1.12x | CN¥123.99 Million |
| 2023 | 10.63% | 18.85% | 0.52x | 1.08x | CN¥255.86 Million |
| 2024 | 13.92% | 22.64% | 0.56x | 1.10x | CN¥1.78 Billion |
Industry Comparison
This section compares Jiangsu Hengrui Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,943,649,877
- Average return on equity (ROE) among peers: 15.51%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Hengrui Medicine Co Ltd (600276) | CN¥60.03 Billion | 43.58% | 0.14x | $45.23 Billion |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $57.63 Million | 31.51% | 1.53x | $477.42 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $44.35 Million | 17.35% | 1.49x | $354.95 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $9.78 Billion | 0.44% | 0.12x | $4.52 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $623.47 Million | 16.22% | 0.40x | $2.45 Billion |
| Wedge Industrial Co Ltd (000534) | $1.54 Billion | 9.43% | 0.69x | $1.19 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.53 Billion | 7.79% | 0.38x | $14.02 Billion |
| Hainan Haiyao Co Ltd (000566) | $471.68 Million | 7.92% | 0.79x | $742.30 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $263.96 Million | 20.90% | 1.39x | $271.23 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.57 Billion | 22.73% | 1.61x | $906.21 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $6.56 Billion | 20.83% | 0.09x | $2.95 Billion |
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more